Clinical trials: Moderate to Severe Osteoarthritis
- Condition Moderate to Severe Osteoarthritis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Low Back Pain, Osteoarthritis
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the efficacy of fasinumab in relieving Chronic low back pain (CLBP) as compared to placebo in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and…
- Trial name
- FACT CLBP 1 (NCT03285646)
- Testing
- Fasinumab
- Where
- 56 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regeneron Pharmaceuticals
Knee Osteoarthritis
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of…
- Trial name
- NCT03122860
- Testing
- SM04690
- Where
- 74 sites in United States
- Volunteers
- 700 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis
Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
The purpose of this phase is to evaluate the long-term safety and tolerability of BTDS. Qualified subjects are started on BTDS 5 and the dose may be titrated, if necessary, to a maximum of BTDS 20 to achieve stable pain control.
- Trial name
- NCT01135524
- Testing
- Buprenorphine transdermal patch
- Where
- 89 sites in United States
- Volunteers
- 196 people
- Sponsor
- Purdue Pharma LP
Low Back Pain, Osteoarthritis
Long-term Open-Label Safety Study to Evaluate EN3409
The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended…
- Conditions
- Low Back Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT01755546
- Testing
- EN3409
- Where
- 57 sites in United States
- Volunteers
- 304 people
- Sponsor
- BioDelivery Sciences International
Knee Osteoarthritis
Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)
This phase 3 study was a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic…
- Trial name
- NCT05603754
- Testing
- Lorecivivint
- Where
- 44 sites in United States
- Volunteers
- 499 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis, Knee
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.
- Trial name
- NCT00833911
- Testing
- Tramadol Once A Day
- Volunteers
- 392 people
- Sponsor
- Labopharm Inc.
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Knee Osteoarthritis
Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis…
- Trial name
- STRIDES-1 (NCT04385303)
- Testing
- Lorecivivint
- Where
- 76 sites in United States
- Volunteers
- 496 people
- Sponsor
- Biosplice Therapeutics, Inc.
Chronic Pain
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results…
- Trial name
- NCT01223365
- Testing
- Hydrocodone ER
- Where
- 54 sites in United States
- Volunteers
- 330 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Osteoarthritis, Knee
Efficacy and Safety Study of Transdermal Therapeutic System (TTS) Fentanyl in Participants With Osteoarthritis Knee Pain
The purpose of this study is to evaluate the efficacy and safety of Transdermal therapeutic system (TTS) fentanyl patches (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01742897
- Testing
- TTS-fentanyl
- Where
- Thailand
- Volunteers
- 35 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Osteoarthritis, Chronic Pain
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
- Trial name
- NCT00420992
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
- Where
- 81 sites in United States
- Volunteers
- 547 people
- Sponsor
- Pfizer
Osteoarthritis
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.
The original objective of this study was to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 micrograms (mcg)/hour (h) in comparison to the buprenorphine transdermal system 5 mcg/h…
- Trial name
- NCT00320801
- Testing
- Buprenorphine transdermal patch
- Where
- 66 sites in United States
- Volunteers
- 188 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis, Back Pain
A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis
The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.
- Trial name
- NCT00784810
- Testing
- Oxycodone/Naloxone, Codeine/Paracetamol
- Where
- United Kingdom
- Volunteers
- 247 people
- Sponsor
- Napp Pharmaceuticals Limited
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.
Osteoarthritis, Knee
Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee
The aim of this study is to evaluate the effectiveness and safety of a combined Traumeel® / Zeel® injection against placebo (saline) in patients with moderate-to-severe pain associated with osteoarthritis of the knee.
- Trial name
- MOZArT (NCT01887678)
- Testing
- Traumeel® / Zeel® Injectable Solution
- Where
- 30 sites in United States
- Volunteers
- 287 people
- Sponsor
- Biologische Heilmittel Heel GmbH
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Knee Osteoarthritis
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic…
- Trial name
- STRIDES-Xray (NCT03928184)
- Testing
- Lorecivivint
- Where
- 99 sites in United States
- Volunteers
- 501 people
- Sponsor
- Biosplice Therapeutics, Inc.
Chronic Pain
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by…
- Trial name
- NCT01240863
- Testing
- Hydrocodone ER
- Where
- 73 sites in United States
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in…
- Trial name
- NCT00312221
- Testing
- Buprenorphine, oxycodone immediate-release
- Where
- 23 sites in United States
- Volunteers
- 418 people
- Sponsor
- Purdue Pharma LP
Knee Osteoarthritis
Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
The primary purpose of this phase 2, placebo-controlled, double-blind, parallel group study was to provide an initial safety evaluation of two intra-articular (IA) injections of SM04690 (each at the dose of 0.07mg per 2mL…
- Trial name
- NCT03727022
- Testing
- SM04690
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Biosplice Therapeutics, Inc.